A Phase III Multicenter Randomized Study of the Efficacy Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy (Pavilion)

Brief description of study

The purpose of this study is to evaluate the effects, good or bad, of a drug called ranibizumab when it is delivered by an ocular (eye) implant (also known as the Port Delivery System with ranibizumab, or PDS) as treatment for diabetic retinopathy (DR) versus routine diagnostic vision tests, photographs of your eye, and eye examinations to monitor your DR. The current approved form of ranibizumab is delivered through regular monthly eye injections.

Clinical Study Identifier: s20-00295
ClinicalTrials.gov Identifier: NCT04503551
Principal Investigator: Yasha S Modi.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.